CytoDyn Announces Encouraging Survival Data in Patients with Metastatic Colorectal Cancer Previously Treated with Leronlimab Jul 01, 2025 8:30am EDT
CytoDyn Announces First Patient Dosed in Phase II Oncology Trial in Colorectal Cancer Jun 24, 2025 8:30am EDT
CytoDyn Announces Data Suggesting Novel Mechanism of Action of Leronlimab for the Treatment of Solid Tumors May 13, 2025 8:30am EDT
CytoDyn Appoints Biotech Veteran Robert E. Hoffman as Chief Financial Officer May 06, 2025 8:30am EDT
CytoDyn Leadership Team To Attend ESMO Breast Cancer Meeting in Munich, Germany Apr 29, 2025 8:30am EDT
CytoDyn Announces Promising Survival Observations in mTNBC Patients Treated with Leronlimab Feb 24, 2025 8:30am EST
CytoDyn Announces Findings of Statistically Significant Fibrosis Reversal Across Studies with SMC Laboratories Feb 06, 2025 8:30am EST
